

# CITATION REPORT

List of articles citing

## Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury

DOI: 10.3390/ijms22020792

International Journal of Molecular Sciences, 2021, 22, .

**Source:** <https://exaly.com/paper-pdf/82827491/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis. <i>Case Reports in Oncology</i> , <b>2021</b> , 14, 733-738	1	1
29	Suppression of EGFR/PKC- $\gamma$ /NF- $\kappa$ B Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 735183	5.3	1
28	Nimotuzumab for COVID-19: case series. <i>Immunotherapy</i> , <b>2021</b> ,	3.8	0
27	Medication-induced Pulmonary Injury: A Scenario- and Pattern-based Approach to a Perplexing Problem. <i>Radiographics</i> , <b>2021</b> , 210146	5.4	3
26	Polyacetylenes from Root Induced Apoptosis of Human Lung Adenocarcinoma Cells and Improved Lung Dysbiosis.. <i>BioMed Research International</i> , <b>2022</b> , 2022, 7713355	3	0
25	Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. <i>Current Medical Research and Opinion</i> , 1-20	2.5	
24	Analysis of adverse drug reactions of Osimertinib in the 2nd-line treatment of EGFR mutant advanced nonsmall cell lung cancer. <b>2022</b> , 11, 69-81		0
23	EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI associated interstitial lung disease in Asian.		
22	Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study. 1-6		0
21	A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Osimertinib.		0
20	A Study of the Relationship Between Interstitial Lung Abnormalities and Osimertinib-induced Lung Injury. <b>2022</b> , 62, 292-298		0
19	Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers. 676-693		0
18	Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report. <b>2022</b> , 23, 11809		1
17	Chitosan Oligosaccharide Prevents Afatinib-Induced Barrier Disruption and Chloride Secretion through Modulation of AMPK, PI3K/AKT, and ERK Signaling in T84 Cells. <b>2022</b> , 14, 4255		1
16	ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. <b>2022</b> , 2, 282-304		0
15	Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review. Publish Ahead of Print,		0
14	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. 1-13		0

- 13 Welcome to the Real World. **2022**, 162, 965-967 ○
- 12 A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. **2022**, 12, ○
- 11 Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats. **2023**, 30, 103522 ○
- 10 Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways. 13, ○
- 9 Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. **2022**, 13, 2183 ○
- 8 Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells. **2023**, 220, ○
- 7 Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. **2023**, 21, ○
- 6 Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database. 1-8 ○
- 5 Afatinib-induced bronchiolitis obliterans. **2023**, 10, 100231 ○
- 4 Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC. 13, ○
- 3 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 2 Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality. **2023**, 23, ○
- 1 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○